SCHEDULE 13G/A: D1 Capital Partners and Daniel Sundheim Disclose 2.9% Stake in Lexeo Therapeutics

D1 Capital Partners L.P. and Daniel Sundheim have filed an amended Schedule 13G, reporting a 2.9% beneficial ownership stake in Lexeo Therapeutics, Inc.

Summary

• D1 Capital Partners L.P. and Daniel Sundheim collectively reported beneficial ownership of 978,652 shares of Lexeo Therapeutics, Inc. Common Stock.
• This represents 2.9% of the company's outstanding Common Stock.
• The percentage is calculated based on 33,196,997 shares of Common Stock reported outstanding as of March 21, 2025, as disclosed in Lexeo Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed on March 24, 2025.
• Both D1 Capital Partners L.P. and Daniel Sundheim share voting and dispositive power over these shares.
• The filing is an Amendment No. 1 to a previous Schedule 13G.

Sentiment

Score: 5

Explanation: The document is a factual ownership disclosure and does not contain information that would significantly alter the sentiment towards the company. The stake is passive and below the 5% threshold for significant influence.

Positives

• The presence of D1 Capital Partners, a significant investment firm, as a shareholder may indicate a level of institutional confidence in Lexeo Therapeutics.

Negatives

• The reported stake of 2.9% is below the 5% threshold typically associated with significant influence or activist positions, suggesting a passive investment.
• The document does not provide context on whether this stake represents an increase or decrease from previous filings, only that it is an amendment.

Risks

• The document itself, being an ownership disclosure, does not detail specific operational or financial risks of Lexeo Therapeutics.

Future Outlook

The document, a beneficial ownership report, does not contain any forward-looking statements or guidance regarding Lexeo Therapeutics, Inc.'s future performance or strategic direction.

Management Comments

• The filing includes a certification from D1 Capital Partners L.P. (signed by Amanda Hector, General Counsel and Chief Compliance Officer) and Daniel Sundheim, stating that the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of the issuer.

Industry Context

This filing is a routine disclosure of beneficial ownership by an institutional investor, D1 Capital Partners, in a publicly traded biotechnology or pharmaceutical company, Lexeo Therapeutics. Such filings provide transparency on significant shareholder positions but do not typically offer insights into the company's operational performance or broader industry trends.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory requirement for passive investors holding between 5% and 20% of a company's stock, or for certain institutional investors holding less than 5% but meeting specific criteria.
• The 2.9% stake reported by D1 Capital Partners is a relatively small passive investment compared to major institutional holdings that often exceed 5% and trigger more detailed Schedule 13D filings, which imply an intent to influence management or control.
• No specific comparable companies, projects, or results are mentioned in this ownership disclosure.

Stakeholder Impact

• This filing provides transparency to shareholders and potential investors regarding the ownership structure of Lexeo Therapeutics, showing that D1 Capital Partners and Daniel Sundheim hold a passive stake.

Next Steps

• The document does not outline any specific future actions, events, or milestones for Lexeo Therapeutics or the reporting persons beyond the regulatory filing itself.

Key Dates

Keywords

Lexeo Therapeutics, D1 Capital Partners, Daniel Sundheim, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing